Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharma (TKPYY)

Takeda Pharma (TKPYY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,919,552
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 60-Month Beta 0.42
  • Price/Sales 1.64
  • Price/Cash Flow N/A
  • Price/Book 1.36
  • Price/Earnings ttm 12.22
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/19
  • Annual Dividend & Yield 0.58 (3.48%)
  • Most Recent Dividend 0.288 on 09/27/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5000 +7.03%
on 12/18/18
19.2300 -13.73%
on 11/26/18
-2.6300 (-13.68%)
since 11/21/18
3-Month
15.5000 +7.03%
on 12/18/18
21.9399 -24.38%
on 09/26/18
-4.3650 (-20.83%)
since 09/21/18
52-Week
15.5000 +7.03%
on 12/18/18
31.2900 -46.98%
on 02/01/18
-11.8100 (-41.58%)
since 12/21/17

Most Recent Stories

More News
Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive...

TKPYY : 16.5900 (-0.90%)
Takeda to Outline Progress on Business Transformation and Priorities at the 38th Annual J.P. Morgan Healthcare Conference

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") will provide an update on the progress of its business transformation and priorities today at the 38th Annual J.P. Morgan Healthcare...

JPM : 134.93 (+0.37%)
TKPYY : 16.5900 (-0.90%)
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019

--- Pre-clinical scientific studies demonstrate potential opportunities to improve upon adeno-associated virus gene therapies for hemophilia and other monogenic diseases

TKPYY : 16.5900 (-0.90%)
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH)...

TKPYY : 16.5900 (-0.90%)
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG(R) (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

--- Median Progression-Free Survival with ALUNBRIG was Three Times Longer than that with Crizotinib -

TKPYY : 16.5900 (-0.90%)
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

--a^' Sustained innovation beyond 2024 based on a promising early stage pipeline and novel research platforms intended to provide transformative benefit for targeted populations with high unmet needs

TKPYY : 16.5900 (-0.90%)
New Analyses from the Phase 3 HELP Study(TM) Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO(R) (lanadelumab-flyo) Injection During Extended Study Treatment Period

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO(R) (lanadelumab-flyo) injection in...

TKPYY : 16.5900 (-0.90%)
Phase 3 Trial of NINLARO(TM) (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

--- Data to be Submitted for Presentation at an Upcoming Medical Meeting -

TKPYY : 16.5900 (-0.90%)
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society of Hematology (ASH) Annual Meeting...

TKPYY : 16.5900 (-0.90%)
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

--a^' Potential to be the First CAR Cell Therapy Approved for Outpatient Administration

TKPYY : 16.5900 (-0.90%)
Trade TKPYY with:

Key Turning Points

2nd Resistance Point 17.1900
1st Resistance Point 16.8900
Last Price 16.5900
1st Support Level 16.3200
2nd Support Level 16.0500

See More

52-Week High 31.2900
Fibonacci 61.8% 25.2582
Fibonacci 50% 23.3950
Fibonacci 38.2% 21.5318
Last Price 16.5900
52-Week Low 15.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar